Quest Diagnostics (DGX)
(Delayed Data from NYSE)
$146.01 USD
-0.83 (-0.57%)
Updated Jul 19, 2024 04:00 PM ET
2-Buy of 5 2
B Value D Growth A Momentum B VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
DGX 146.01 -0.83(-0.57%)
Will DGX be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for DGX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for DGX
Patterson (PDCO) Expands AI Solutions in Canada via Alliance
Edwards Lifesciences (EW) Buys Innovalve to Boost TMVR Solutions
DGX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio
Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio
AMN Healthcare (AMN) Unveils ShiftWise Flex Manager Hub App
Other News for DGX
Quest Diagnostics Market Position and Earnings Potential: Analyst Pito Chickering’s Outlook amidst Inflationary Challenges and Growth Strategies
Tesla, Alphabet, GM, Ford Lead Earnings Parade This Week As Market Struggles To Sustain The Summer Rally
Labcorp, Quest among health firms to cite impact from CrowdStrike issue
Lisata to use Haystack technology to evaluate pancreatic cancer asset certepetide
Fiduciary Management Q2 2024 Investment Strategy Outlook